Misonix CEO Michael A. McManus, Jr. to Retire

8/29/16

Michael A. McManus, Jr.

Misonix, Inc. (NASDAQ: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, neurosurgery, wound debridement, skull based surgery, laparoscopic surgery and other surgical applications, announced that, effective September 2, 2016, Michael A. McManus, Jr. is resigning as a Director and Chairman of the Board of Directors of Misonix and retiring as the Company's President and Chief Executive Officer.

Effective September 2, 2016, Stavros G. Vizirgianakis, a member of the Misonix Board of Directors, will serve, on an unpaid basis, as Misonix's interim Chief Executive Officer. Misonix and Mr. Vizirgianakis are in negotiations for him to accept employment as Misonix's full-time Chief Executive Officer.

Mr. Vizirgianakis has served on the Misonix Board since May 2013. He holds a 5.7% ownership stake in Misonix. He has been involved with Misonix as early as September 2010 as the owner of a company acting as Misonix's South African distributor.

Mr. Vizirgianakis said, "I am honored to be asked to serve as interim Chief Executive Officer and am excited about the Company's products and future. The Misonix team will no doubt continue to put forth their best efforts to design, develop and manufacture cutting-edge technology for the medical device field."

Mr. McManus commented, "After 16 years as CEO, I retire with gratitude for the dedicated professionals who have contributed to the Company's innovation and growth, and with great confidence in the Company's future potential and the leadership of Stavros Vizirgianakis. I look forward to doing whatever I can to be helpful to him as he transitions to his new role."

About Misonix

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $1.5 billion annually; Misonix's proprietary ultrasonic medical devices are used in spine surgery, neurosurgery, orthopedic surgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

Recent Deals

Interested in advertising your deals? Contact Edwin Warfield.